CPRX vs. XPEL

Last updated Apr 1, 2026

Compare and contrast key facts about Catalyst Pharmaceuticals, Inc. (CPRX) and XPEL, Inc. (XPEL).

Performance

CPRX vs. XPEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Catalyst Pharmaceuticals, Inc. (CPRX) and XPEL, Inc. (XPEL). The values are adjusted to include any dividend payments, if applicable.

CPRX vs. XPEL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
CPRX Catalyst Pharmaceuticals, Inc.	6.08%	11.84%	24.15%	-9.62%	174.74%	102.69%	-10.93%	95.31%	-50.90%	272.38%
XPEL XPEL, Inc.	-11.32%	24.96%	-25.83%	-10.34%	-12.04%	32.43%	251.95%	140.10%	335.82%	0.00%

Fundamentals

Market Cap CPRX : $3.15B XPEL : $1.23B
EPS CPRX : $1.68 XPEL : $1.85
PE Ratio CPRX : 14.71 XPEL : 23.92
PEG Ratio CPRX : 0.26 XPEL : 1.67
PS Ratio CPRX : 5.35 XPEL : 2.57
PB Ratio CPRX : 3.30 XPEL : 4.30
Total Revenue (TTM) CPRX : $588.99M XPEL : $476.20M
Gross Profit (TTM) CPRX : $726.82M XPEL : $201.02M
EBITDA (TTM) CPRX : $257.78M XPEL : $79.75M

Returns By Period

In the year-to-date period, CPRX achieves a 6.08% return, which is significantly higher than XPEL's -11.32% return. Over the past 10 years, CPRX has underperformed XPEL with an annualized return of 35.35%, while XPEL has yielded a comparatively higher 49.29% annualized return.

CPRX

• 1D: 4.12%
• 1M: 7.28%
• YTD: 6.08%
• 6M: 25.69%
• 1Y: 2.10%
• 3Y*: 14.30%
• 5Y*: 40.58%
• 10Y*: 35.35%

XPEL

• 1D: 10.90%
• 1M: 3.85%
• YTD: -11.32%
• 6M: 33.84%
• 1Y: 50.65%
• 3Y*: -13.32%
• 5Y*: -4.17%
• 10Y*: 49.29%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

CPRX vs. XPEL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

CPRX

CPRX Risk / Return Rank: 41
CPRX Sharpe Ratio Rank: 44
CPRX Sortino Ratio Rank: 38
CPRX Omega Ratio Rank: 37
CPRX Calmar Ratio Rank: 42
CPRX Martin Ratio Rank: 41

XPEL

XPEL Risk / Return Rank: 74
XPEL Sharpe Ratio Rank: 77
XPEL Sortino Ratio Rank: 77
XPEL Omega Ratio Rank: 71
XPEL Calmar Ratio Rank: 70
XPEL Martin Ratio Rank: 72

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

CPRX vs. XPEL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Catalyst Pharmaceuticals, Inc. (CPRX) and XPEL, Inc. (XPEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	CPRX	XPEL	Difference
Sharpe ratio Return per unit of total volatility	0.06	1.11	-1.05
Sortino ratio Return per unit of downside risk	0.32	1.91	-1.59
Omega ratio Gain probability vs. loss probability	1.04	1.22	-0.18
Calmar ratio Return relative to maximum drawdown	0.01	1.36	-1.35
Martin ratio Return relative to average drawdown	0.02	3.73	-3.71
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

CPRX vs. XPEL - Sharpe Ratio Comparison

The current CPRX Sharpe Ratio is 0.06, which is lower than the XPEL Sharpe Ratio of 1.11. The chart below compares the historical Sharpe Ratios of CPRX and XPEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	CPRX	XPEL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.06	1.11	-1.05
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.85	-0.08	+0.92
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.56	0.77	-0.21
Sharpe Ratio (All Time) Calculated using the full available price history	0.08	0.08	0.00

Correlation

The correlation between CPRX and XPEL is 0.10, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

CPRX vs. XPEL - Dividend Comparison

Neither CPRX nor XPEL has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

CPRX vs. XPEL - Drawdown Comparison

The maximum CPRX drawdown since its inception was -94.25%, smaller than the maximum XPEL drawdown of -99.77%. Use the drawdown chart below to compare losses from any high point for CPRX and XPEL.

Drawdown Indicators

	CPRX	XPEL	Difference
Max Drawdown Largest peak-to-trough decline	-94.25%	-99.77%	+5.52%
Max Drawdown (1Y) Largest decline over 1 year	-27.29%	-31.79%	+4.50%
Max Drawdown (5Y) Largest decline over 5 years	-45.37%	-75.62%	+30.25%
Max Drawdown (10Y) Largest decline over 10 years	-64.87%	-75.62%	+10.75%
Current Drawdown Current decline from peak	-5.89%	-56.35%	+50.46%
Average Drawdown Average peak-to-trough decline	-52.51%	-52.38%	-0.13%
Ulcer Index Depth and duration of drawdowns from previous peaks	15.10%	11.61%	+3.49%

Volatility

CPRX vs. XPEL - Volatility Comparison

The current volatility for Catalyst Pharmaceuticals, Inc. (CPRX) is 10.39%, while XPEL, Inc. (XPEL) has a volatility of 14.09%. This indicates that CPRX experiences smaller price fluctuations and is considered to be less risky than XPEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	CPRX	XPEL	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.39%	14.09%	-3.70%
Volatility (6M) Calculated over the trailing 6-month period	23.71%	27.25%	-3.54%
Volatility (1Y) Calculated over the trailing 1-year period	34.96%	46.31%	-11.35%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	48.24%	55.11%	-6.87%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	62.81%	63.87%	-1.06%

Financials